The US FDA has approved Medtronic's implantable electrical stimulation device for treating patients with a rare but severe and often life-threatening form of gastroparesis, a gastrointestinal disorder marked by chronic vomiting and nausea.
The company's Enterra therapy, which was approved under humanitarian device exemption (HDE) regulations, uses a neurostimulator, which is implanted beneath the skin in the lower abdomen, to deliver pulses to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?